LX102-C01 / Innostellar Biotherap - LARVOL DELTA

Intravitreal Gene Therapy with LX102-C01 in Neovascular Age-Related Macular Degeneration: A Phase I Dose-Escalation Study of 12-Month Safety and Efficacy Outcomes. (PubMed, Ophthalmol Sci) - P=N/A | "LX102-C01 showed a favorable safety profile and potential efficacy in this preliminary 52-week study, with no observed macular atrophy, suggesting short-term tolerability of gene therapy associated anti-VEGF expression. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • P1 data • Age-related Macular Degeneration • Gene Therapies • Genetic Disorders • Hematological Disorders • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Vasculitis • Wet Age-related Macular Degeneration

Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P=N/A | N=6 | Active, not recruiting | Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration